Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by yorgosGKon Apr 12, 2018 3:10pm
234 Views
Post# 27875310

Called Colwell - had a wonderful chat. I urge you to call 2

Called Colwell - had a wonderful chat. I urge you to call 2I was speaking with Graeme from Colwell earlier this week and congratulated him on his new account, KALY.

What I grasped:

He brings a very special and vital service to the shareholders of KALY. He has a lot of experience in dealing with small to medium cap company’s and has a wonderful track record (also went over some success stories). Along with his business partner Christina - they will give exposure to KALY in the Canadian markets. Up until now KALY has been doing it alone so with the Colwel firm the sky is the limit. Graeme’s & Christina’s media connections also want us on BNN; and he stressed to me they are on it already (no timeline given). Another topic of interest that stood out to me is that Graeme really knows the markets, he urged me that moving forward there will be a strategy in place for news, PR and exposure. That was comforting to hear, especially because that means there will be more frequent updates and news released.<br>
Although a call is just a call, I can honestly say he gained my confidence as a shareholder. He understands what it takes to raise money and is here for a long-term ride (that isn’t taking anything away from KALY today and its short-term future). Graeme’s story on what he thinks of KALY is fantastic and I urge everyone to give him a call to hear it from him; just what he is able to bring for us (its too much to type it out here).<br>
This addition (practically) relieves our CEO Rob of IR duties, and he can now can spend his efforts on the company. If history tells us that all successful companies (especially biotech ones) have investor relation services, it was only a matter of time before KALY got their hands on one. This is yet another step in the right direction that our word class board has taken. Pain and simple – IMO there are way too many successful people on our board and doing Salzman trials for this thing to fail. Not to mention our $10M Talent takeover. <br>
There will be very exiting things to come from KALY in the near to long term future. Out of all my current holdings, I am mostly excited about KALY. This is just the beginning. Also P.S. Don’t let this short-term noise get to you. Level2 is shaping up fantastically for us and it is clear that the penny chasing bears are leaving in bunches, opening doors to bigger and better bulls. Just wait until Graeme and Christina get their first major fund manager to come on board .
 
CHEERS! GLTA

Bullboard Posts